Search IconSearch

Ezetimibe Adds Incremental Benefit to Statin Therapy

Further lowering LDL reduces risk in post-ACS patients


The IMPROVE-IT trial found that adding ezetimibe (Zetia®) to statin therapy further lowered LDL and with it, cardiovascular risk in post-acute-coronary-syndrome patients.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Although statins remain the most effective medications for lowering cholesterol, IMPROVE-IT showed that a non-statin with a different mechanism of lowering LDL does provide some benefit,” says Steven Nissen, MD, Chairman of Cardiovascular Medicine at Cleveland Clinic. “However, the benefit was small, took a long time to occur and came at a relatively high cost.”

The study, presented at the American Heart Association 2014 Scientific Sessions, randomized more than 18,000 patients to simvastatin 40 mg with or without ezetimibe. The primary end point was a composite of cardiovascular death, myocardial infarction, unstable angina requiring hospitalization, revascularization or stroke. After seven years of treatment, 32.7 percent of patients taking the dual therapy experienced the endpoint, versus 34.7 percent of patients taking the statin alone—a 6.4 percent lower risk, or an absolute risk reduction of 2 percent, over seven years.

Dr. Nissen calculated that the cost of ezetimibe to prevent a single non-fatal event was approximately $900,000.

Interestingly, adding ezetimibe did not reduce mortality rates. However, this drug did reduce the relative risk of myocardial infarction by 13 percent and the relative risk of ischemic stroke by 21 percent.

“These findings demonstrate that this method of LDL lowering is potentially useful in a very high-risk population,” says Dr. Nissen.

IMPROVE-IT was the first trial to lower patients’ LDL levels into unknown territory–<70 mg/dL in both arms. Simvastatin reduced LDL from a mean of 95 mg/dL to 69.9 mg/dL; those taking simvastatin plus ezetimibe reached 53.2 mg/dL after one year. A moderate difference remained throughout the seven-year trial.

Moreover, the very low levels of LDL appeared safe.


Related Articles

New Guideline Helps Evaluate Risk in Patients With Chest Pain

Further acute testing not needed if ECG and high-sensitivity troponin are negative

New Head of Vascular Medicine Looks to Enhance Collaborative Caregiving

Scott Cameron, MD, PhD, also brings wide-ranging research interests to bear

Stroke Risk in Cardiac Surgery: New Guidance for Averting a Dreaded Complication

AHA statement is first comprehensive document on perioperative stroke reduction

20-HVI-1898975 Singh_Guidelines on CV imaging in athletes_CQD_650x450_993744768
First Formal Guidance Issued on Multimodality Cardiac Imaging in Young Athletes

Recommendations help distinguish exercise-induced remodeling from pathology

Trio of Studies at Virtual HRS Meeting Showcase Catheter Ablation Advances

Pushing the envelope in ablation of atrial fibrillation, ventricular tachycardia